Aphidicolin decreases ex vivo resistance to cytosine arabinoside in childhood acute leukaemia.

Jean M. Sargent; Christine J. Williamson; Isabelle Hubeek; Alena W. Elgie; Colin G. Taylor; Monique L. Den Boer; Godefridus J. Peters; Gertjan L. Kaspers

doi:https://doi.org/10.3892/or.10.6.2027

Aphidicolin decreases ex vivo resistance to cytosine arabinoside in childhood acute leukaemia.

Jean M. Sargent, Christine J. Williamson, Isabelle Hubeek, Alena W. Elgie, Colin G. Taylor, Monique L. Den Boer, Godefridus J. Peters, Gertjan L. Kaspers

Research output: Contribution to journal › Article › Academic › peer-review

4 Citations (Scopus)

Abstract

In order to assess the effect of the DNA polymerase inhibitor aphidicolin on resistance to cytosine arabinoside, blast cells from 15 children with ALL and 9 with AML were exposed to a range of concentrations of ara-C +/- aphidicolin. Cell survival was measured using the MTT assay. Aphidicolin significantly increased sensitivity to ara-C in blast cells from both ALL (p=0.001) and AML (p<0.01). The median fold increase (sensitisation ratio) for ALL was 3.4 (range 1.2-13.6) compared to 12.4-fold (range 6.0-148) for AML blasts (p=0.005). There was a striking relationship between increasing ara-C resistance and increasing effect of aphidicolin in AML (p<0.001) but not ALL (p>0.05). These remarkable results suggest that aphidicolin should be considered for future clinical trials as a modulator of ara-C resistance, particularly in AML.

Original language	English
Pages (from-to)	2027-2031
Number of pages	5
Journal	Oncology Reports
Volume	10
Issue number	6
DOIs	https://doi.org/10.3892/or.10.6.2027
Publication status	Published - 2003

Access to Document

https://doi.org/10.3892/or.10.6.2027

Cite this

@article{c2d63df52ac84677a7862f032399641a,

title = "Aphidicolin decreases ex vivo resistance to cytosine arabinoside in childhood acute leukaemia.",

abstract = "In order to assess the effect of the DNA polymerase inhibitor aphidicolin on resistance to cytosine arabinoside, blast cells from 15 children with ALL and 9 with AML were exposed to a range of concentrations of ara-C +/- aphidicolin. Cell survival was measured using the MTT assay. Aphidicolin significantly increased sensitivity to ara-C in blast cells from both ALL (p=0.001) and AML (p<0.01). The median fold increase (sensitisation ratio) for ALL was 3.4 (range 1.2-13.6) compared to 12.4-fold (range 6.0-148) for AML blasts (p=0.005). There was a striking relationship between increasing ara-C resistance and increasing effect of aphidicolin in AML (p<0.001) but not ALL (p>0.05). These remarkable results suggest that aphidicolin should be considered for future clinical trials as a modulator of ara-C resistance, particularly in AML.",

author = "Sargent, {Jean M.} and Williamson, {Christine J.} and Isabelle Hubeek and Elgie, {Alena W.} and Taylor, {Colin G.} and {Den Boer}, {Monique L.} and Peters, {Godefridus J.} and Kaspers, {Gertjan L.}",

year = "2003",

doi = "https://doi.org/10.3892/or.10.6.2027",

language = "English",

volume = "10",

pages = "2027--2031",

journal = "Oncology Reports",

issn = "1021-335X",

publisher = "Cognizant Communication Corporation",

number = "6",

}

TY - JOUR

T1 - Aphidicolin decreases ex vivo resistance to cytosine arabinoside in childhood acute leukaemia.

AU - Sargent, Jean M.

AU - Williamson, Christine J.

AU - Hubeek, Isabelle

AU - Elgie, Alena W.

AU - Taylor, Colin G.

AU - Den Boer, Monique L.

AU - Peters, Godefridus J.

AU - Kaspers, Gertjan L.

PY - 2003

Y1 - 2003

N2 - In order to assess the effect of the DNA polymerase inhibitor aphidicolin on resistance to cytosine arabinoside, blast cells from 15 children with ALL and 9 with AML were exposed to a range of concentrations of ara-C +/- aphidicolin. Cell survival was measured using the MTT assay. Aphidicolin significantly increased sensitivity to ara-C in blast cells from both ALL (p=0.001) and AML (p<0.01). The median fold increase (sensitisation ratio) for ALL was 3.4 (range 1.2-13.6) compared to 12.4-fold (range 6.0-148) for AML blasts (p=0.005). There was a striking relationship between increasing ara-C resistance and increasing effect of aphidicolin in AML (p<0.001) but not ALL (p>0.05). These remarkable results suggest that aphidicolin should be considered for future clinical trials as a modulator of ara-C resistance, particularly in AML.

AB - In order to assess the effect of the DNA polymerase inhibitor aphidicolin on resistance to cytosine arabinoside, blast cells from 15 children with ALL and 9 with AML were exposed to a range of concentrations of ara-C +/- aphidicolin. Cell survival was measured using the MTT assay. Aphidicolin significantly increased sensitivity to ara-C in blast cells from both ALL (p=0.001) and AML (p<0.01). The median fold increase (sensitisation ratio) for ALL was 3.4 (range 1.2-13.6) compared to 12.4-fold (range 6.0-148) for AML blasts (p=0.005). There was a striking relationship between increasing ara-C resistance and increasing effect of aphidicolin in AML (p<0.001) but not ALL (p>0.05). These remarkable results suggest that aphidicolin should be considered for future clinical trials as a modulator of ara-C resistance, particularly in AML.

UR - http://www.scopus.com/inward/record.url?scp=2642547615&partnerID=8YFLogxK

U2 - https://doi.org/10.3892/or.10.6.2027

DO - https://doi.org/10.3892/or.10.6.2027

M3 - Article

C2 - 14534738

SN - 1021-335X

VL - 10

SP - 2027

EP - 2031

JO - Oncology Reports

JF - Oncology Reports

IS - 6

ER -

Aphidicolin decreases ex vivo resistance to cytosine arabinoside in childhood acute leukaemia.

Abstract

Access to Document

Other files and links

Cite this